Bortezomib is effective to treat acute humoral rejection after liver transplantation

Transplantation Proceedings

Volumn 44, Issue 2, 2012, Pages 529-531

  Lee, C F ^a   Eldeen, F Z ^a   Chan, K M ^a   Wu, T H ^a   Soong, R S ^a   Wu, T J ^a   Chou, H S ^a   Lee, W C ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; RITUXIMAB;

ACUTE HUMORAL REJECTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LIVER GRAFT REJECTION; LIVER NECROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PNEUMONIA; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ACUTE DISEASE; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PULSE THERAPY, DRUG; PYRAZINES; RETROSPECTIVE STUDIES; STEROIDS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863258204     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.01.051     Document Type: Article

References (17)

1. S. Faguer, N. Kamar, C. Guilbeaud-Frugier Rituximab therapy for acute humoral rejection after kidney transplantation Transplantation 83 2007 1277
2. N.B. White, S.M. Greenstein, A.W. Cantafio Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection Transplantation 78 2004 772
3. M.J. Everly, J.J. Everly, B. Susskind Proteasome inhibition reduces donor- specific antibody levels Transplant Proc 41 2009 105
4. M.J. Everly, J.J. Everly, B. Susskind Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection Transplantation 86 2008 1754
5. K.M. Chan, C.S. Lee, T.J. Wu Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation Transplantation 91 2011 e29
6. R.D. Gordon, J.J. Fung, S. Iwatsuki Immunological factors influencing liver graft survival Gastroenterol Clin North Am 17 1988 53
7. P.T. Donaldson, L.J. Thomson, A. Heads IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation An assessment by cytotoxicity and flow cytometry Transplantation 60 1995 1016
8. S.K. Takemoto, A. Zeevi, S. Feng National conference to assess antibody- mediated rejection in solid organ transplantation Am J Transplant 4 2004 1033
9. A.J. Demetris, K.P. Batts, A.P. Dhillon Banff schema for grading liver allograft rejection: an international consensus document Hepatology 25 1997 658
10. H. Sakashita, H. Haga, E. Ashihara Significance of C4d staining in ABO- identical/compatible liver transplantation Mod Pathol 20 2007 676
11. E.J. Ramos, H.S. Pollinger, M.D. Stegall The effect of desensitization protocols on human splenic B-cell populations in vivo Am J Transplant 7 2007 402
12. D.K. Perry, J.M. Burns, H.S. Pollinger Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production Am J Transplant 9 2009 201
13. K. Neubert, S. Meister, K. Moser The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat Med 14 2008 748
14. J.F. San Miguel, R. Schlag, N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 2008 906
15. R.C. Walsh, J.J. Everly, P. Brailey Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection Transplantation 89 2010 277
16. J. Adams The proteasome: a suitable antineoplastic target Nat Rev Cancer 4 2004 349
17. M.D. Stegall, P.G. Dean, J. Gloor Mechanisms of alloantibody production in sensitized renal allograft recipients Am J Transplant 9 2009 998